Historique des études cardiovasculaires: de l'UGDP… aux dernières études

[en] An increasing number of cardiovascular outcome studies in type 2 diabetes are now available. Schematically, they aimed either at investigating the protective effect of intensifying glucose control on both microangiopathic and macroangiopathic complications, or at proving the cardiovascular safety and if possible the efficacy of one specific antidiabetic agent. The UGDP study suggested an increased coronary risk of first-generation sulfonylureas, which was not confirmed by the UKPDS. The latter landmark study emphasized the cardiovascular protection provided by metformin. The PROactive trial reported favourable results, but which were controverted, with pioglitazone. ACCORD, ADVANCE, and VADT were unable to demonstrate a reduction in major cardiovascular events with the intensification of blood glucose control, and suggested that a too strong intensification leading to hypoglycemia could increase the cardiovascular mortality. Recent studies have proven the cardiovascular safety of insulin glargine, lixisenatide and gliptins (non-inferiority vs. placebo), whereas they showed a significant reduction in major cardiovascular events with liraglutide and semaglutide, and a remarkable reduction in cardiovascular and all-cause mortality as well as in the risk of heart failure with empagliflozin. Several ongoing large prospective trials should provide answers to remaining important questions in a near future. © 2017 Elsevier Masson SAS

Disciplines :

Human health sciences: Multidisciplinary, general & others

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

Historique des études cardiovasculaires: de l'UGDP… aux dernières études

Alternative titles :

[en] Historical perspectives of cardiovascular trials: From UGDP… to recent studies

Publication date :

2017

Journal title :

Médecine des Maladies Métaboliques

ISSN :

1957-2557

eISSN :

2214-8477

Publisher :

Elsevier Masson SAS

Volume :

Pages :

2S15-2S26

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 21 December 2018

Statistics

Number of views

47 (8 by ULiège)

Number of downloads

517 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

[1] Scheen, A.J., Charbonnel, B., Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 40 (2014), 176–185.
[2] Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein, H.C., Miller, M.E., Byington, R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008), 2545–2559.
[3] Goldfine, A.B., Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 359 (2008), 1092–1095.
[4] Nissen, S.E., Wolski, K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471 [Erratum in: N Engl J Med 2007;357:100].
[5] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
[6] Scheen, A.J., Antidiabétiques oraux dans le traitement du diabète de type 2: perspectives historique et médico-économique. Médecine des maladies Métaboliques 9 (2015), 186–197.
[7] Holman, R.R., Sourij, H., Califf, R.M., Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383 (2014), 2008–2017 [Erratum in: Lancet 2014;383:2212].
[8] Ferrannini, E., DeFronzo, R.A., Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 36 (2015), 2288–2296.
[9] Schernthaner, G., Schernthaner-Reiter, M.H., Schernthaner, G.H., EMPA-REG and other cardiovascular outcome trials of glucose-lowering agents: implications for future treatment strategies in type 2 diabetes mellitus. Clin Ther 38 (2016), 1288–1298.
[10] University Group Diabetes Program (UGDP) Research Group. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: Sections I and II. Diabetes 19:Suppl 2 (1970), 747–830.
[11] Marso, S.P., Bain, S.C., Consoli, A., et al. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
[12] The Diabetes Control and Complications Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
[13] Nathan, D.M., Cleary, P.A., Backlund, J.Y., et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005), 2643–2653.
[14] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853 [Erratum in: Lancet 1999;354:602].
[15] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865 [Erratum in: Lancet 1998;352:1558].
[16] Scheen, A.J., Editorial: Que penser de tous ces essais de non-infériorité pour démontrer la sécurité cardiovasculaire des nouveaux médicaments antidiabétiques ?. Rev Med Suisse 11 (2015), 1515–1516.
[17] Kilo, C., Miller, J.P., Williamson, J.R., The crux of the UGDP. Spurious results and biologically inappropriate data analysis. Diabetologia 18 (1980), 179–185.
[18] Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
[19] Dormandy, J.A., Charbonnel, B., Eckland, D.J., et al. PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005), 1279–1289.
[20] Skyler, J.S., PROactive: A sad tale of inappropriate analysis and unjustified interpretation. Clin Diabetes 24 (2006), 63–65.
[21] Scheen, A.J., Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract 98 (2012), 175–186.
[22] Home, P.D., Pocock, S.J., Beck-Nielsen, H., et al., RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373 (2009), 2125–2135.
[23] Mahaffey, K.W., Hafley, G., Dickerson, S., et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 166 (2013), 240–249.e1.
[24] Scheen, A.J., Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?. Nature Clin Pract Endocrinol Metab 4 (2008), 260–261.
[25] Kernan, W.N., Viscoli, C.M., Furie, K.L., et al., IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
[26] DeFronzo, R.A., Chilton, R., Norton, L., et al. Revitalization of pioglitazone: the optimal agent to be combined with a sodium-glucose co-transporter-2 inhibitor. Diabetes Obes Metab 18 (2016), 454–462.
[27] ADVANCE Collaborative Group, Patel, A., MacMahon, S., Chalmers, J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
[28] Duckworth, W., Abraira, C., Moritz, T., et al., VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139 [Erratum in: N Engl J Med 2009;361:1028].
[29] Hayward, R.A., Reaven, P.D., Wiitala, W.L., et al., VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 372 (2015), 2197–2206 [Erratum in: N Engl J Med 2015;373:198].
[30] Zoungas, S., Chalmers, J., Neal, B., et al., ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371 (2014), 1392–1406.
[31] NAVIGATOR Study Group, Holman, R.R., Haffner, S.M., McMurray, J.J., et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362 (2010), 1463–1476 [Erratum in: N Engl J Med 2010;362:1748].
[32] ORIGIN Trial Investigators, Gerstein, H.C., Bosch, J., Dagenais, G.R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 (2012), 319–328.
[33] Monami, M., Ahrèn, B., Dicembrini, I., Mannucci, E., Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15 (2013), 112–120.
[34] Hoogwerf, B.J., Manner, D.H., Fu, H., et al. Perspectives on some controversies in cardiovascular disease risk assessment in the pharmaceutical development of glucose-lowering medications. Diabetes Care 39:Suppl.2 (2016), S219–S227.
[35] White, W.B., Cannon, C.P., Heller, S.R., et al., EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
[36] Scirica, B.M., Bhatt, D.L., Braunwald, E., et al., SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
[37] Green, J.B., Bethel, M.A., Armstrong, P.W., et al., TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242 [Erratum in: N Engl J Med 2015;373:586].
[38] Scirica, B.M., Braunwald, E., Raz, I., et al., SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130 (2014), 1579–1588 [Erratum in: Circulation 2015;132:e198].
[39] Scheen, A.J., Gliptines, sécurite cardiovasculaire et insuffisance cardiaque: le point après l’étude TECOS. Rev Med Suisse 11 (2015), 1526–1531.
[40] Standl, E., Erbach, M., Schnell, O., Dipeptidyl-peptidase-4 inhibitors and heart failure: class effect, substance-specific effect, or chance effect?. Curr Treat Options Cardiovasc Med, 16, 2014, 353.
[41] Scheen, A.J., Wallemacq, C., Jandrain, B., Ernest, P., Protection cardiovasculaire du patient diabétique de type 2: d'EMPA-REG OUTCOME à LEADER. Rev Med Suisse 12 (2016), 1370–1375.
[42] Zinman, B., Wanner, C., Lachin, J.M., et al., EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
[43] Scheen, A.J., Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes Metab 42 (2016), 71–76.
[44] Scheen, A.J., Reappraisal of the diuretic effect of empagliflozin in EMPA-REG OUTCOME: Comparison with classic diuretics. Diabetes Metab 42 (2016), 224–233.
[45] Ponikowski, P., Voors, A.A., Anker, S.D., et al., Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200 [Erratum in: Eur Heart J 2016 Dec 30. Epub ahead of print].
[46] Pfeffer, M.A., Claggett, B., Diaz, R., et al., ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
[47] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
[48] Scheen AJ. Semaglutide, a promising new glucagon-like peptide-1 receptor agonist. Lancet Diabetes Endocrinol 2017 Jan 16 [Epub ahead of print].
[49] Sattar, N., McLaren, J., Kristensen, S.L., et al. SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339 [Erratum in: Diabetologia 2016;59:1573-4].
[50] Kang, Y.M., Jung, C.H., Cardiovascular effects of glucagon-like peptide-1 receptor agonists. Endocrinol Metab (Seoul) 31 (2016), 258–274.
[51] Chiasson, J.L., Josse, R.G., Gomis, R., et al., STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003), 486–494.
[52] Holman, R.R., Bethel, M.A., Chan, J.-C., et al., ACE Study Group. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. Am Heart J 168 (2014), 23–29.e2.